Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AG1002
- Development stage
- Unknown
- Lead developer
- Beijing Aige Stem Cell Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Parenteral
01
Overview
AG1002 is an investigational stem cell therapy developed by Beijing Aige Stem Cell Technology (also known as Aegle Stem Cell Technology) for the treatment of localized scleroderma, also referred to as focal scleroderma. The therapy received clinical trial implied approval (IND approval) from the Chinese National Medical Products Administration (NMPA) in December 2023. A Phase Ia clinical trial is projected to commence in the third quarter of 2025. AG1002 is designed to leverage the regenerative and immunomodulatory potential of stem cells to address the localized skin hardening and underlying fibrosis characteristic of the condition.
Beyond the preview
Go deeper on AG1002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AG1002.